Literature DB >> 8031071

Penetration of piperacillin-tazobactam into cancellous and cortical bone tissues.

S J Incavo1, P J Ronchetti, J H Choi, H Wu, M Kinzig, F Sörgel.   

Abstract

The penetration characteristics of piperacillin-tazobactam into cortical and cancellous bone tissues were investigated in 10 patients undergoing total hip replacement. The concentration ratios of piperacillin/tazobactam were 9.4 +/- 1.8 in cancellous bone tissue and 8.0 +/- 2.2 in cortical bone tissue, which were close to the 8:1 ratio of drugs administered. The mean ratios of drug concentrations in bone and plasma for cancellous and cortical tissue were 23 and 18%, respectively, for piperacillin and 26 and 22%, respectively, for tazobactam. The concentrations of tazobactam achieved are sufficient to exert anti-beta-lactamase activity and supportive of clinical trials involving bone and joint infections, including those caused by beta-lactamase-producing pathogens.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8031071      PMCID： PMC284568          DOI： 10.1128/AAC.38.4.905

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery.

Authors:  M Kinzig; F Sörgel; B Brismar; C E Nord
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

Review 2.  Pharmacokinetics of antibiotics in tissues and tissue fluids: a review.

Authors:  O Cars
Journal:  Scand J Infect Dis Suppl       Date:  1990

3.  Penetration of amoxycillin and clavulanic acid into bone.

Authors:  R J Grimer; M R Karpinski; J M Andrews; R Wise
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

4.  Piperacillin therapy for serious bacterial infections.

Authors:  D J Winston; W Murphy; L S Young; W L Hewitt
Journal:  Am J Med       Date:  1980-08       Impact factor: 4.965

5.  Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Authors:  R N Jones; M A Pfaller; P C Fuchs; K Aldridge; S D Allen; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

6.  Penetration of amoxycillin/clavulanate into human bone.

Authors:  K Weismeier; D Adam; H D Heilmann; P Koeppe
Journal:  J Antimicrob Chemother       Date:  1989-11       Impact factor: 5.790

7.  A problem in the interpretation of beta-lactam antibiotic levels in tissues.

Authors:  D M Ryan; O Cars
Journal:  J Antimicrob Chemother       Date:  1983-09       Impact factor: 5.790

8.  Comparative activities of the beta-lactamase inhibitors YTR 830, sodium clavulanate, and sulbactam combined with amoxicillin or ampicillin.

Authors:  S C Aronoff; M R Jacobs; S Johenning; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1984-10       Impact factor: 5.191

Review 9.  The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.

Authors:  F Sörgel; M Kinzig
Journal:  J Antimicrob Chemother       Date:  1993-01       Impact factor: 5.790

Review 10.  Piperacillin sodium: antibacterial spectrum, pharmacokinetics, clinical efficacy, and adverse reactions.

Authors:  C L Fortner; R S Finley; S C Schimpff
Journal:  Pharmacotherapy       Date:  1982 Nov-Dec       Impact factor: 4.705
View more
  8 in total

1.  Adjuvant arthritis-induced changes on ampicillin binding in serum and tissues under the influence of non-steroidal anti-inflammatory drugs in rats.

Authors:  E Tigka; I Daskala; G Rallis; S Anagnostopoulou; C Tesseromatis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Oct-Dec       Impact factor: 2.441

2.  Kinetics of piperacillin and tazobactam in ventricular cerebrospinal fluid of hydrocephalic patients.

Authors:  R Nau; M Kinzig-Schippers; F Sörgel; S Schinschke; R Rössing; C Müller; H Kolenda; H W Prange
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 3.  Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 4.  Systemic antibiotic therapy for chronic osteomyelitis in adults.

Authors:  Brad Spellberg; Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2011-12-12       Impact factor: 9.079

Review 5.  Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.

Authors:  Nikolas J Onufrak; Alan Forrest; Daniel Gonzalez
Journal:  Clin Ther       Date:  2016-07-20       Impact factor: 3.393

Review 6.  Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.

Authors:  Cornelia B Landersdorfer; Jürgen B Bulitta; Martina Kinzig; Ulrike Holzgrabe; Fritz Sörgel
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Intermittent Short-Term Infusion vs. Continuous Infusion of Piperacillin: Steady State Concentrations in Porcine Cervical Spine Tissue Evaluated by Microdialysis.

Authors:  Elisabeth Krogsgaard Petersen; Pelle Hanberg; Martin Knudsen; Sara Kousgaard Tøstesen; Andrea René Jørgensen; Kristina Öbrink-Hansen; Kjeld Søballe; Maiken Stilling; Mats Bue
Journal:  Antibiotics (Basel)       Date:  2022-07-07

8.  The association between radiological spreading pattern and clinical outcomes in necrotizing external otitis.

Authors:  W Leentje van der Meer; Ahmed B Bayoumy; Josje J Otten; Jerome J Waterval; Henricus P M Kunst; Alida A Postma
Journal:  J Otol       Date:  2022-06-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.